Increased growth of CO2-fixing thermophilic bacteria

Abstract

Methods for increasing the growth of Moorella sp. bacteria, genetically modified bacteria derived from such methods, and the use of such bacteria to metabolize carbon-containing substrates, as appropriate, in the production of biochemicals, are provided.

Description

[Technical field]

[0001] The present invention relates to the use of thermophilic bacteria for the fixation of CO2 and the production of biochemicals, as well as methods to increase the growth of such bacteria by genetic modification, leading to increased efficiency of CO2 fixation. [Background technology]

[0002] Bulk chemicals are produced unsustainably by the decomposition of fossil fuels on a scale of millions of tons. At the same time, humanity emits more than 40 gigatons of CO2 into the atmosphere every year, leading to the disturbing effects of climate change and rising temperatures. Technologies are emerging that propose to capture industrial CO2 emissions and convert carbon into value. However, efficiency and feasibility limit their implementation. Traditional techniques for CO2 capture include filters, planting trees, or growing algae. Filters require expensive catalysts that are sensitive to impurities in the CO2 gas, while planting trees and growing algae have very low land area efficiency.

[0003] To develop processes that meet these limitations, the application of bacteria, especially bacteria that function at high temperatures, is expected to be of great importance. High incubation temperatures reduce the risk of contamination with unwanted microorganisms. Fermentation usually requires large amounts of cooling water. For fermentation using thermophilic bacteria, this requirement does not apply. Overall, thermophilic fermentation processes have characteristics that result in significantly lower capital and operational expenditures when compared to other bio-based production processes.

[0004] Acetogenic bacteria are a group of bacteria that grow with CO2 (or CO) as the sole carbon source. The growth of acetogenic bacteria is directly linked to the fixation of CO2. One of the organisms, Moorella thermoacetica, has interesting properties for fixing CO2 from an industrial point of view. Although CO2 fixation is very efficient in this organism, the growth rate is limited. Strains with higher growth rates would be very beneficial to make CO2 fixation more efficient. In industrial production, there are fluctuations in gas supply as well as gradients in bioreactors. M. thermoacetica is known to die or sporulate when nutrients or substrates are limiting. This results in inactive passages and greatly reduces the overall efficiency. Developing cells that can survive for longer periods or under more stressful conditions and also recover faster (when nutrients or substrates become available) would benefit the efficiency of the process. WO 2011 / 019717 A1 (Mascoma Corp.) relates to vectors encoding selectable markers and their use in replacing target genes, such as spo0A, with such markers in, for example, thermophilic bacterial host cells. WO 2020 / 157487 A2 (University of Nottingham) relates to genetic constructs for use in controlling gene expression, such as Spo0A, in sporulating cells.

[0005] Stage 0 sporulation protein A homolog (Spo0A) is a protein involved in the regulation of bacterial sporulation. Spo0A binds to DNA and controls the expression of many genes (Molle et al., Mol. Microbiol.; 50:1683-1701 2003). Spo0A activates the sporulation cascade in various genera, including Bacilli and Clostridia. Deletion of the spo0A gene in Bacillus subtilis has been reported to prevent sporulation (Spigelman et al., J. Bacteriol.; 172:5011-5019 1990).

[0006] The HTH-type transcription factor SinR (SinR) has been reported to function as both a negative and positive regulator of developmental processes induced at the end of vegetative growth in response to nutrient depletion. For example, SinR acts as a repressor of Spo0A. During stationary phase, SinR monomers form complexes with either SinI or SlrR, while SinR tetramers act as transcriptional repressors of matrix genes during vegetative growth. SinI is an anti-repressor and is able to sequester SinR, whereas the SlrR-SinR complex relieves repression of the matrix operon and instead represses genes required for planktonic growth (Kearns et al., Mol. Microbiol.; 55:739-749 2005; Chai et al., Mol. Microbiol.; 74:876-887 2009; Chai et al., Genes Dev.; 24:754-765 2010). Summary of the Invention

[0007] The present inventors have found that the growth of Moorella sp. bacteria can be increased by genetic modification of the genes encoding SinR and Spo0A. Thus, the present invention generally relates to a method for enhancing the growth of Moorella sp. bacteria, thereby increasing their efficiency of CO2 fixation and biochemical production.

[0008] Thus, in a first aspect, the present invention relates to a method for increasing the growth rate of a bacterium belonging to the Moorella species, comprising introducing into said bacterium one or more genetic modifications so as to reduce or eliminate the expression and / or activity of stage 0 sporulation protein A homologue (Spo0A) in said bacterium.

[0009] In some embodiments, the one or more genetic modifications include a genetic modification that reduces or eliminates expression of a Spo0A protein in the bacterium.

[0010] In some embodiments, the spoOA gene is deleted.

[0011] In some embodiments, the method further comprises introducing one or more genetic modifications into the bacterium to express a mutant of SinR in the bacterium, wherein the SinR mutant has at least 90% sequence identity to SEQ ID NO:2 and comprises an amino acid other than V at a position corresponding to position 198 in SEQ ID NO:2, preferably wherein the amino acid is F, I, Y, or W, more preferably wherein the amino acid is F, and wherein the SinR mutant provides a decreased duration of lag phase and / or an increased growth rate of the bacterium when compared to SEQ ID NO:2.

[0012] In a second aspect, the present invention relates to a method for reducing the duration of the lag phase and / or increasing the growth rate of a bacterium belonging to the Moorella species, comprising introducing into the bacterium one or more genetic modifications so as to express in said bacterium a mutant of an HTH-type transcriptional regulator (SinR), wherein the SinR mutant has at least 90% sequence identity with SEQ ID NO:2 and comprises an amino acid other than valine (V) at the position corresponding to position 198 in SEQ ID NO:2, and wherein the SinR mutant provides a reduction in the duration of the lag phase and / or an increase in the growth rate of said bacterium when compared to SEQ ID NO:2.

[0013] In some embodiments, the amino acid at the position corresponding to 198 in SEQ ID NO:2 is phenylalanine (F), isoleucine (I), tyrosine (Y), or tryptophan (W).

[0014] In some embodiments, the amino acid at the position corresponding to position 198 in SEQ ID NO:2 is F. In some embodiments of the first and second aspects, the Moorella species is selected from: (a) Moorella thermoacetica; (b) Moorella thermoautotrophica; (c) a bacterial strain having an average nucleotide identity based on a MUMmer alignment (ANIm) score of at least about 96.5% compared to M. thermoacetica strain DSM 512T; (d) a bacterial strain having an average nucleotide identity based on a MUMmer alignment (ANIm) score of at least about 96.5% compared to M. thermoacetica strain DSM 2955; and (e) (a) and (b); (a) and (c); (a) and (d); (a), (b) and (c), or all combinations of (a) through (d).

[0015] In a third aspect, the present invention relates to a genetically modified bacterium obtained or obtainable by a method according to an embodiment of the first or second aspect.

[0016] In a fourth aspect, the present invention relates to a bacterium belonging to the species M. thermoacetica and / or M. thermoautotrophica, which has been genetically modified to reduce or eliminate expression and / or activity of Spo0A in the bacterium, wherein the reduced expression and / or activity is relative to its expression and / or activity in wild-type M. thermoacetica and / or M. thermoautotrophica.

[0017] In a fifth aspect, the present invention relates to a bacterium belonging to the species M. thermoacetica and / or M. thermoautotrophica, said bacterium being genetically modified to comprise a transgene encoding a mutant of SinR, said SinR mutant having at least 90% sequence identity with SEQ ID NO: 2 and comprising an amino acid other than V at the position corresponding to position 198 in SEQ ID NO: 2, said SinR mutant providing a reduced duration of the lag phase and / or an increased growth rate of said bacterium when compared to SEQ ID NO: 2. The bacterium may be M. thermoacetica ATCC 39073 strain or a strain derived therefrom, such as M. thermoacetica 39073-HH strain.

[0018] In a sixth aspect, the present invention relates to a bacterium belonging to the species M. thermoacetica and / or M. thermoautotrophica, said bacterium comprising: (a) a mutant of SinR having at least 90% sequence identity to SEQ ID NO:2 and comprising an amino acid other than V at a position corresponding to position 198 in SEQ ID NO:2, wherein the SinR mutant provides a decreased duration of lag phase and / or an increased growth rate of the bacterium when compared to SEQ ID NO:2; (b) relates to a bacterium having reduced or eliminated expression and / or activity of Spo0A, wherein said reduced expression and / or activity is relative to its expression and / or activity in wild-type M. thermoacetica and / or M. thermoautotrophica.

[0019] In some embodiments of the fourth and sixth aspects, the spoOA gene is deleted.

[0020] In some embodiments of the fifth and sixth aspects, the amino acid at the position corresponding to 198 in SEQ ID NO:2 is F.

[0021] In a seventh aspect, the present invention relates to the use of a bacterium according to any one of aspects 3 to 6 for metabolizing a carbon-containing substrate, optionally in the production of a biochemical product.

[0022] In some embodiments, i) the carbon-containing substrate is CO and / or CO2; ii) the biochemical is selected from C1-C4 alcohols, C1-C4 ketones, C1-C4 aldehydes, C1-C4 carboxylic acids, and any mixture thereof; or iii) Both i) and ii).

[0023] In some embodiments of the first through seventh aspects, the bacterium is M. thermoacetica ATCC 39073 strain or a strain derived therefrom, such as M. thermoacetica 39073-HH strain. [Brief description of the drawings]

[0024] [Figure 1] Figure 1: Schematic diagram of the growth curve of a bacterial culture as determined by optical density (OD) measurements. The growth of a bacterial culture can be divided into four phases: lag phase, log phase, stationary phase, and death phase. [Diagram 2] Figure 2: Plasmid map of the spo0A knockout plasmid. [Diagram 3] Figure 3: Growth curves of the WT and Δspo0A strains as a function of time in hours (h). A; Individual measurements of triplicate cultures are shown. B; Average growth curves, light patterns indicate standard deviations. C; Same as B, but showing optical density on a logarithmic scale. [Figure 4]Figure 4: Structural analysis of the SinR-SinI complex from Bacillus. A: SinR-SinI complex from Bacillus (PDB ID: 1b0n). The HTH domain from SinR is shown without any pattern, the oligomerization domain is patterned with circles, and SinI is patterned with a pentamer. B: The pattern scheme is the same as in A, and the side chains of T60 and L61 are shown in stick representation with a small black triangle pattern. C: Zoom-in of L61 and visualization of the L to F mutation. The proposed structure of phenylalanine is shown in grey stick representation. The visible disks and patterns indicate the pairwise overlap of atomic van der Waals radii. Short lines or small disks are indicated where atoms are nearly touching or slightly overlapping. The large disk with a cross indicates significant van der Waals overlap. All others are between their ends. D: Zoom-in of T60 and visualization of the T to F mutation. Left: Hydrogen bond between T60 in SinR and E14 in SinI. Center: T to F mutation with phenylalanine in the most common rotamer. Right: T to F mutation with phenylalanine in the most favored rotamer. Disks and patterns as shown in C. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0025] definition As used herein, the term "Moorella spp." refers to any member of the group of species belonging to the bacterial genus Moorella and classified as belonging to the phylum Firmicutes. Moorella spp. are typically thermophilic, anaerobic, endospore-forming, and can be isolated, for example, from hot springs. A non-limiting list of Moorella spp. can be found at the National Center for Biotechnology Information (World Wide Web (www) address ncbi.nlm.nih.gov / Taxonomy / Browser / wwwtax.cgi?id=44260; accessed July 1, 2021, incorporated herein by reference in its entirety) and elsewhere herein.

[0026] Particularly preferred are the acetogenic (gas fermenting) species Moorella thermoacetica (M. thermoacetica), a species previously known as Clostridium thermoaceticum, and Moorella thermoautotrophica (M. thermoautotrophica), and all strains derived therefrom, including strains isolated in laboratory environments or from natural sources. Although M. thermoacetica and M. thermoautotrophica are often considered to be two distinct species, genomic comparisons have shown that M. thermoautotrophica strains can be reclassified as strains of M. thermoacetica (Redl et al., Front. Microbiol.; 10:3070 2020). Therefore, as used herein, M. thermoacetica can refer to both strains of bacteria that are generally classified as M. thermoacetica and strains of bacteria that can be classified as M. thermoacetica strains by genetic analysis, such as strains of M. thermoautotrophica. Methods for determining whether a bacterial strain belongs to the M. thermoacetica species are described below. Non-limiting examples of M. thermoacetica strains include M. thermoacetica ATCC 39073, M. thermoacetica ATCC 39073-HH (Genbank accession number CP031054, preferably version CP031054.1), and M. thermoacetica Y72. As used herein, "wild type M. thermoacetica and / or M. thermoautotrophica" refers to any naturally occurring strain of M. thermoacetica and / or M. thermoautotrophica. For example, a wild-type M. thermoacetica genome typically includes a spoOA gene, a gene encoding a SinR protein (preferably having a valine at the amino acid position corresponding to 198 in SEQ ID NO:2), or both.

[0027] As used herein, the term "SinR" or "HTH-type transcription regulator SinR" includes all mutants of SinR, but is not limited to mutants encoded by Moorella spp. bacteria. An example of a mutant of SinR encoded by Moorella thermoacetica is the protein of UniProt ID: A0A5B7YPR1 (SEQ ID NO: 2). See Table 1. As used herein, the term "SinR" refers to a protein having at least 80%, such as 85%, such as 90%, such as 91%, such as 92%, such as 93%, such as 94%, such as 95%, such as 96%, such as 97%, such as 98%, and such as 99% sequence identity to SEQ ID NO: 2. Preferably, prior to any genetic modification by the methods described herein, the Moorella spp. cell to be modified contains a native SinR protein, which preferably contains a valine at the amino acid position corresponding to position 198 in SEQ ID NO: 2. Preferably, M. thermoacetica SinR is encoded by a gene having the European Nucleotide Archive (ENA) locus tag MothHH_01753 (SEQ ID NO: 1). See Table 1.

[0028] As used herein, the term "Spo0A" or "Stage 0 sporulation protein A homolog" refers to an endogenous protein of related Moorella species. An example of Spo0A is M. thermoacetica Spo0A with UniProt ID: A0A5B7YPG0 (SEQ ID NO: 4). See Table 1. Another example of Spo0A is M. thermoacetica Spo0A with UniProt ID: A0A1D7XBE2. As used herein, the term "Spo0A" refers to a protein having at least 80%, such as 85%, such as 90%, such as 91%, such as 92%, such as 93%, such as 94%, such as 95%, such as 96%, such as 97%, such as 98%, and 99% sequence identity to SEQ ID NO: 4. Preferably, M. thermoacetica Spo0A is encoded by a gene with ENA locus tag MothHH_01617 (SEQ ID NO: 3). See Table 1.

[0029] The term "gene" refers to a nucleic acid sequence that encodes a cellular function such as a protein, and may include regulatory sequences preceding (5' non-coding sequences) and following (3' non-coding sequences) the coding sequence. A "transgene" is a native or heterologous gene that has been introduced into a cell by genetic engineering techniques, for example by transformation. Gene names are written herein in italic text with lowercase first letters (e.g., spo0A), whereas protein names are written in regular text with capitalized first letters (e.g., Spo0A).

[0030] [Table 1]

[0031] As used herein, "genetic modification" refers to the introduction of genetically inherited changes into the genome of a host cell. Examples of changes include mutations in genes and regulatory sequences, and mutations in coding and non-coding DNA sequences. "Mutation" includes the deletion, substitution and insertion of nucleic acid or nucleic acid fragments in genome.

[0032] A "variant" of a parent or reference protein comprises one or more mutations, such as amino acid substitutions, insertions and deletions, when compared to the parent or reference protein. Typically, a variant has a high sequence identity to the amino acid sequence of the parent or reference protein, for example at least about 70%, such as at least about 80%, for example at least about 84%, such as at least about 85%, for example at least about 87%, for example at least about 90%, for example at least about 93%, such as at least about 95%, for example at least about 96%, for example at least about 97%, for example at least about 98%, for example at least about 99%, over the entire length, as appropriate, at least over the functionally or catalytically active portion.

[0033] Unless otherwise indicated, "sequence identity" as used herein with respect to amino acid sequences is defined as follows: ref -N dif )·100 / N ref (In the formula, N ref is the number of residues in one of the two sequences, and N dif is determined by comparing two optimally aligned sequences of equal length according to the n-th order (n is the number of non-identical residues in the two sequences when they are aligned over their entire length and in the same direction). Thus, the amino acid sequence GSTDYTQNWA (SEQ ID NO: 19) is aligned with the sequence GSTGYTQAWA (SEQ ID NO: 20; dif =2 and n ref =10) and has 80% sequence identity.

[0034] Sequence identity can be determined in conventional ways, for example by the "search for similarity" method of Smith and Waterman (Adv. Appl. Math.; 2:482 1981), by the "search for similarity" method of Pearson and Lipman (Proc. Natl. Acad. Sci. USA; 85:2444 1988), by using the CLUSTAL W algorithm of Thompson et al. (Nucleic Acids Res.; 22:467380 1994) using these algorithms (GAP, BESTFIT, FASTA, and TFASTA from the Wisconsin Genetics Software Package, Genetics Computer Group), or by the Needleman-Wunsch algorithm (Needleman and Wunsch, J. Mol. Biology, vol. 14, no. 1, 2001) as implemented in the Needle program of the EMBOSS package (EMBOSS: The European Molecular Biology Open Software Suite, Rice et al., Trends Genet.; 16:276-277 2000). Biol.; 48:443-453 1970), for example as provided at the European Bioinformatics Institute website (www.ebi.ac.uk). The BLAST algorithm (Altschul et al., Mol. Biol.; 215:403-410 1990), whose software can be obtained through the National Center for Biotechnology Information (www.ncbi.nlm.nih.gov / ), may also be used. When using any of the above algorithms, default parameters for "window" length, gap penalties, etc. may be used.

[0035] A residue in an amino acid sequence that "corresponds to" a particular reference residue in a reference amino acid sequence is a residue that aligns with the reference residue, as determined, for example, by use of sequence alignment software as described in the previous section.

[0036] The term "expression," as used herein, refers to the process by which a gene is transcribed into mRNA, and may include the subsequent translation of the mRNA into an amino acid sequence, i.e., a protein or polypeptide.

[0037] As used herein, "reducing expression" of a gene in a host cell means that the level of mRNA or protein encoded by the gene is significantly reduced in the host cell compared to a control, usually by at least 25%, such as at least 50%, such as at least 75%, such as at least 90%, such as at least 95%.Usually, when the reduction in expression is obtained by genetic modification in the host cell, the control is an unmodified host cell.

[0038] "Loss of expression" of a gene in a host cell means that the mRNA or protein encoded by that gene is essentially absent, nonexistent, or undetectable in the host cell.

[0039] The term "knockdown," as used herein, refers to any of a variety of techniques that result in reduced expression of a gene in a host cell, such as the introduction of a mutation in a promoter.

[0040] The term "knockout", as used herein, refers to any of a variety of techniques that result in the loss of expression of a gene in a host cell, such as the introduction of a mutation in a gene or the deletion of a gene. The term "deletion", as used herein, refers to the partial or complete removal of the coding sequence of a gene, which results in either the loss of expression of that gene or the expression of a non-functional gene product.

[0041] The term "activity" or "function", as used herein, and when referring to an activity or function of a protein, unless nothing further is specified, may mean any activity or function of that protein, such as catalytic activity, binding activity, inhibitory activity, etc.

[0042] As used herein, "reducing the activity" of a protein in a host cell means that one or more specific activities of the protein are significantly reduced in the host cell compared to a control, usually at least 25%, such as at least 50%, such as at least 75%, such as at least 90%, such as at least 95%.Usually, when the reduction in activity is obtained by genetic modification in the host cell, the control is an unmodified host cell. "Eliminating the activity" of a protein in a host cell means that one or more specific activities of the protein are essentially absent, absent or undetectable in the host cell.

[0043] Genetic modification that reduces or eliminates the activity of target protein can include mutation or deletion in the coding sequence of the protein, which results in the expression of non-functional or less functional protein.Furthermore, genetic modification that reduces or eliminates the expression and / or activity of target gene as used herein can be indirect, meaning that they are not genetic modifications in the gene itself.Such genetic modification can include, for example, the introduction of a nucleic acid sequence that reduces the expression of target gene, for example, an inhibitor that inhibits the expression of target gene.

[0044] Standard recombinant DNA and molecular cloning techniques useful for carrying out embodiments of the present invention are well known in the art and are described, for example, by Sambrook, J., Fritsch, EF, and Maniatis, T.(2012).Molecular cloning: A laboratory manual, 4th ed. Cold Spring Harbor Laboratory: Cold Spring Harbor, New York, and by Silhavy, TJ, Bennan, ML, and Enquist, LW(1984).Experiments with gene fusions. Cold Spring Harbor Laboratory: Cold Spring Harbor, New York.Techniques for targeted genome editing, such as knocking out targeted genes in bacterial genomes, include clustered regularly interspaced short palindromic repeats (CRISPR)-based systems, such as CRISPR-Cas9.

[0045] The "growth rate" of bacteria, as used herein, is a measure that reflects the number of cell divisions per unit time. The growth rate can be calculated based on the optical density (OD) measurement of the bacterial culture at 600 nm, where the growth rate can be expressed as the change in OD per unit time, for example, per hour.

[0046] As used herein, the term "lag phase" refers to the first of the four phases of bacterial growth: lag phase, log phase, stationary phase, and death phase when referring to the lag phase of bacteria. The lag phase is the phase in which bacteria usually adapt to new external conditions before they start replicating (entering the log phase). Non-limiting examples of new external conditions include inoculating a new medium and adding nutrients, such as a carbon source, to an existing culture. During the lag phase, cell division is usually low or absent.

[0047] As used herein, "metabolism" refers to the consumption of a substrate in one or more metabolic processes, optionally catalyzed by one or more enzymes.

[0048] The term "substrate" as used herein refers to a molecule on which an enzyme acts to form a product, converting the substrate in the process. When used in the context of a biosynthetic pathway, the term "substrate" refers to the molecule or molecules on which the first enzyme in the referenced pathway acts. A "carbon-containing substrate" is a substrate that contains at least one carbon atom, such as CO or CO2.

[0049] As used herein, "biochemicals" refers to molecules that can be produced by biological processes. In the context of the present invention, Moorella sp. bacteria can be used to produce biochemicals by the action of their native endogenous enzymes or after genetic modification, such as the insertion of one or more transgenes that code for specific enzymes suitable for producing the biochemical of interest.

[0050] Specific embodiments of the present invention As described in Example 1, the growth rate of M. thermoacetica was increased by deletion of the gene encoding Spo0A (Example 1; FIG. 3 and Table 3).

[0051] The regulation of gene expression to control the growth rate of cells is complex and delicately regulated, usually involving many genes / proteins. However, here, the deletion of a single gene, the gene encoding Spo0A, increased the growth rate of M. thermoacetica. Moreover, the gene was deleted by replacing it with a gene encoding an antibiotic resistance protein under the control of a common promoter. Such alterations usually slow the growth of the modified organism, but in this case the opposite effect was observed. Moreover, contrary to what has been shown in previous reports (see Background Art), the deletion of spo0A in M. thermoacetica did not result in a reduction in sporulation. This observation suggests that the increase in growth rate observed upon deletion of spo0A in M. thermoacetica was not due to a reduction in the metabolic burden associated with the sporulation cascade, since the cascade was still functional.

[0052] As described in Example 2, the V198F mutation in SinR decreased the duration of the lag phase of M. thermoacetica upon inoculation into fresh medium after a longer incubation period, leading to a more rapid recovery from quiescence (Example 2). Furthermore, it was found that V198 mutations such as V198F in M. thermoacetica SinR can affect the stability of the protein, its affinity for the anti-repressor SinI and / or its ability to oligomerize (see Example 2, FIG. 4 and Tables 4 and 5).

[0053] Thus, the inventors have identified a method to enhance the growth of M. thermoacetica bacteria (by increasing the growth rate and / or decreasing the duration of the lag phase). In M. thermoacetica, there is a direct link between growth and fixation of CO2. The present invention provides strains with enhanced growth, and thereby enhanced fixation of CO2. Furthermore, these strains may be modified to contain one or more enzymes for the production of a biochemical of interest, thereby resulting in increased production of such biochemical.

[0054] In addition to increasing CO2 fixation and biochemical production, advantages of using the method according to the invention for these purposes include:

[0055] - The high cultivation temperature of M. thermoacetica has several advantages, as described in the Background section, including reduced risk of contamination, higher conversion rates, no need for cooling water, and significantly lower capital and operational expenses when compared to other bio-based production processes.

[0056] - Cells that are able to recover faster after being subjected to stressful situations are well suited for use in bioreactors as this allows for a greater degree of fluctuation and gradients (nutrients, pH and substrates) in the bioreactor.

[0057] - In some embodiments, no genes or operons need to be overexpressed, which represents an increased metabolic load. These engineered strains maintain high metabolic activity throughout the fermentation.

[0058] method In some aspects, the invention relates to methods of enhancing growth of Moorella sp. bacteria by introducing genetic modifications into the bacteria to affect expression and / or activity of Spo0A or to express mutant versions of SinR.

[0059] The growth of Moorella sp. bacteria can be enhanced by increasing the bacterial growth rate (the number of cell divisions per unit time) or by decreasing the duration of the lag phase (the time it takes for the bacteria to start replicating after they have adapted to new external conditions), or by a combination of both. Both growth enhancing methods increase the fixation of CO2 and, where appropriate, the production of the biochemical of interest.

[0060] Bacterial growth measurement Bacterial growth is easily measured by standard techniques, including measuring the optical density (OD) at 600 nm, as used in the examples. Continuous measurements can be used to generate graphs from which the duration of the lag phase and the growth rate can be determined. To determine the duration of the lag phase, the OD (as a measure of cell number) of the bacterial culture should be followed from the time the cells are exposed to new external conditions, for example by inoculating a new medium, until the cells enter the exponential growth phase (log phase). For the calculation of the growth rate, the graph is shown in logarithmic scale (see FIG. 1). The growth rate (μ) can be calculated from two data points derived from the linear part of the graph (exponential or log phase): the OD value at time point 1 (t1, OD1) and the OD value at time point 2 (t2, OD2), where t2>t1. The growth rate can then be calculated according to formula I:

[0061]

number

[0062] Genetic modification Spo0A: In one aspect, the present invention relates to a method for increasing the growth rate of a bacterium belonging to the genus Moorella, comprising introducing into the bacterium one or more genetic modifications to reduce or eliminate expression and / or activity of stage 0 sporulation protein A homologue (Spo0A) in the bacterium.

[0063] The expression and activity of Spo0A in such bacteria can be determined by those skilled in the art using standard techniques. For the determination of the expression level of Spo0A mRNA or protein, techniques such as quantitative polymerase chain reaction (qPCR) and Western blot can be used. To quantify the activity of Spo0A in bacteria, it is first necessary to determine which activity should be quantified. As a regulator of sporulation, Spo0A binds to DNA and controls the expression of many genes (Molle et al., Mol. Microbiol.; 50:1683-1701 2003). Thus, the activity of Spo0A can be examined by evaluating the expression of a selection of genes, including genes such as abrB, spoIIA, spoIIG, and spoIIE, for example, by gene microarray or using a reporter gene system containing known Spo0A binding motifs.

[0064] In some embodiments, the expression of Spo0A in such bacteria is reduced, for example, compared to the expression level of spo0A in the bacteria prior to the introduction of genetic modification, the expression level in a reference bacterial cell, or a control, for example, a control value from a textbook or literature. In a further embodiment, the expression of Spo0A is reduced in the bacteria by at least 25%, for example at least 50%, for example at least 75%, for example at least 90%, for example at least 95%. The expression of Spo0A can be reduced, for example, by knocking down the spo0A gene, for example, by introducing a mutation in its promoter or in the translation initiation region, such as a ribosome binding site, by using CRISPR interference (CRISPRi), a CRISPR technique using catalytically inactive Cas enzymes, by contacting bacterial cells with an antisense sequence that disrupts the transcription or translation of the gene, or by deleting a gene encoding a transcription factor that activates the transcription of spo0A, or by introducing a nucleic acid sequence encoding a repressor that inhibits the transcription of spo0A.

[0065] In some embodiments, the expression of Spo0A is eliminated. It means that Spo0A mRNA, Spo0A protein, or both are essentially absent, absent, or undetectable in bacteria. The expression of Spo0A can be eliminated, for example, by knocking out the spo0A gene, for example, by mutating the gene, for example, by introducing a premature stop codon into the coding sequence, or by deleting the gene (which, as used herein, can mean either partial or complete removal of the coding sequence of the gene). In some embodiments, spo0A can be knocked out using techniques such as lambda red-mediated recombination, P1 phage transduction, single-stranded oligonucleotide recombineering / MAGE technology (see, for example, Datsenko and Wanner, 2000; Thomason et al., 2007; Wang et al., 2009) and CRISPR-based technology. In some embodiments, spo0A can be knocked out by transforming bacteria with a knockout vector and replacing the gene in the chromosome using homologous recombination, as described in Example 1. In some embodiments, the expression of Spo0A can be abolished by mutating or deleting the promoter of the gene. In some embodiments, the expression of Spo0A can be abolished by using a catalytically inactive mutant of CRISPR or by expressing an antisense RNA that inhibits the expression or translation of Spo0A, for example. Examples of Spo0A proteins and the genes encoding them, particularly Moorella species, are provided herein. Endogenous genes encoding Spo0A proteins in other Moorella species, including each Moorella species specifically disclosed herein, can be identified using methods known in the art, for example, based on gene homology.

[0066] Introduction of vectors into bacterial host cells can be accomplished, for example, by protoplast transformation (see, e.g., Chang and Cohen, Mol. Gen. Genet.; 168:111-115 1979), using competent cells (see, e.g., Young and Spizizen, J. Bacteriol.; 81:823-829 1961 or Dubnau and Davidoff-Abelson, J. Mol. Biol.; 56:209-221 1971), electroporation (see, e.g., Shigekawa and Dower, Biotechniques; 6:742-751 1988), or conjugation (see, e.g., Koehler and Thome, J. Bacteriol.; 169:5771-5278 1987).

[0067] In some embodiments, the activity of Spo0A is reduced. In further embodiments, the activity of Spo0A is reduced by at least 25%, such as at least 50%, such as at least 75%, such as at least 90%, such as at least 95% in the bacterium. In some embodiments, the activity of Spo0A is eliminated. It means that one or more specific activities of Spo0A are essentially absent, absent or undetectable in the bacterium. The activity of Spo0A can be reduced or eliminated, for example, by introducing a mutation or deletion in the coding sequence of spo0A, which results in the expression of a non-functional or less functional protein.

[0068] SinR: In one aspect, the present invention relates to a method for reducing the duration of the lag phase and / or increasing the growth rate of a bacterium belonging to the Moorella species, comprising introducing one or more genetic modifications into the bacterium to express a mutant of the HTH-type transcriptional regulator SinR (SinR) in the bacterium, wherein the SinR mutant has at least 90% sequence identity with SEQ ID NO:2 and comprises an amino acid other than valine (V) at a position corresponding to position 198 in SEQ ID NO:2, and wherein the SinR mutant provides a reduced duration of the lag phase and / or an increased growth rate of the bacterium when compared to SEQ ID NO:2.

[0069] In some embodiments, the amino acid at the position corresponding to position 198 in SEQ ID NO:2 is I. In some embodiments, the amino acid at the position corresponding to position 198 in SEQ ID NO:2 is M. In some embodiments, the amino acid at the position corresponding to position 198 in SEQ ID NO:2 is V. In some embodiments, the amino acid at the position corresponding to position 198 in SEQ ID NO:2 is Y. In some embodiments, the amino acid at the position corresponding to position 198 in SEQ ID NO:2 is C. In some embodiments, the amino acid at the position corresponding to position 198 in SEQ ID NO:2 is W. In some embodiments, the amino acid at the position corresponding to position 198 in SEQ ID NO:2 is T. In some embodiments, the amino acid at the position corresponding to position 198 in SEQ ID NO:2 is A. In some embodiments, the amino acid at the position corresponding to position 198 in SEQ ID NO:2 is P. In some embodiments, the amino acid at the position corresponding to position 198 in SEQ ID NO:2 is R. In some embodiments, the amino acid at the position corresponding to position 198 in SEQ ID NO:2 is E. In some embodiments, the amino acid at the position corresponding to position 198 in SEQ ID NO:2 is H. In some embodiments, the amino acid at the position corresponding to position 198 in SEQ ID NO:2 is K. In some embodiments, the amino acid at the position corresponding to position 198 in SEQ ID NO:2 is N. In some embodiments, the amino acid at the position corresponding to position 198 in SEQ ID NO:2 is Q. In some embodiments, the amino acid at the position corresponding to position 198 in SEQ ID NO:2 is D. In some embodiments, the amino acid at the position corresponding to position 198 in SEQ ID NO:2 is G. In some embodiments, the amino acid at the position corresponding to position 198 in SEQ ID NO:2 is S.

[0070] In a preferred embodiment, the amino acid at the position corresponding to 198 in SEQ ID NO:2 is F.

[0071] In some embodiments, the SinR mutant has at least 91% sequence identity to SEQ ID NO:2, such as 92%, for example 93%, for example 94%, for example 95%, for example 96%, for example 97%, for example 98%, and for example 99% sequence identity.

[0072] In some embodiments, a vector encoding a SinR mutant is introduced into a bacterial cell by transformation, using techniques described elsewhere herein, as appropriate. Once introduced, the gene encoding the SinR mutant can be maintained as a chromosomal integrant or on an autonomously replicating extrachromosomal vector.

[0073] Optionally, the endogenous sinR gene can be knocked out, for example, according to methods known in the art or described elsewhere herein.

[0074] Optionally, the endogenous sinR gene may remain unmodified. Preferably, the endogenous sinR gene has a valine at the amino acid position corresponding to position 198 in SEQ ID NO:2.

[0075] Preferably, a suitable promoter is selected for the transformation of the bacterial host cell to control the expression of the SinR mutant. The promoter may be native or heterologous to the bacterial host cell, i.e., the promoter may be from the same species as the host cell or from a different species than the host cell, respectively. The promoter may be a constitutive or inducible promoter. A constitutive promoter allows for continuous protein expression, whereas an inducible promoter allows for conditional protein expression. Using an inducible promoter, protein expression may be conditional on the presence of a particular molecule, the presence or absence of light, or a particular temperature. Promoters that can be used to control protein expression in Moorella species include the constitutive promoter PG3PD, which is derived from M. thermoacetica and normally controls the expression of glyceraldehyde-3-phosphate dehydrogenase. Other suitable promoters are known or can be identified by those skilled in the art using well-known techniques.

[0076] In some embodiments, a SinR mutant containing an amino acid other than valine (V) at the position corresponding to position 198 in SEQ ID NO:2 can be generated by introducing one or more mutations into the gene encoding SinR on the bacterial chromosome by site-directed mutagenesis, which can be accomplished, for example, by using homologous recombination-based techniques.

[0077] Transformation can be confirmed using methods well known in the art. Such methods include, for example, whole genome sequencing, Northern blot or PCR amplification of DNA or mRNA, immunoblotting for expression of gene products, or other suitable analytical methods to check the presence or expression of introduced nucleic acid sequences. Expression levels can be further optimized to obtain sufficient expression using methods well known in the art.

[0078] Spo0A+SinR: In some aspects of the present invention, the genetic modification of Spo0A and the genetic modification of SinR, whose modification is described above, are combined in the same cell.Thus, the Moorella sp. bacterium according to the present invention may, for example, comprise the SinR mutant as described herein, or may lack the spo0A gene due to deletion.Any and all aspects and embodiments of the various genetic modifications as described herein may be combined in any and all possible combinations.

[0079] In one aspect, the present invention relates to a bacterium belonging to the species M. thermoacetica and / or M. thermoautotrophica, the bacterium being (a) a mutant of SinR having at least 90% sequence identity to SEQ ID NO:2 and comprising an amino acid other than V at a position corresponding to position 198 in SEQ ID NO:2, wherein the SinR mutant provides a decreased duration of the lag phase and / or an increased growth rate of the bacterium when compared to SEQ ID NO:2; (b) relates to a bacterium having reduced or eliminated expression and / or activity of Spo0A, wherein the reduced expression and / or activity is relative to its expression and / or activity in wild-type M. thermoacetica and / or M. thermoautotrophica.

[0080] In a preferred embodiment, the spoOA gene is deleted and the amino acid at the position corresponding to position 198 in SEQ ID NO:2 is F.

[0081] Genetically modified bacteria In some embodiments, the present invention relates to Moorella sp. bacteria that have been genetically modified to affect the expression and / or activity of SpoOA and / or to express a mutant form of SinR in the bacterium.

[0082] Genetic modifications in bacteria can be generated by techniques well known in the art and as described elsewhere herein.

[0083] In one embodiment, the genetically modified bacterium can be any bacterium belonging to the genus Moorella.The species are Moorella thermoacetica, Moorella glycerini, Moorella humiferrea, Moorella mulderi, Moorella perchloratireducens, Moorella stamsii, Moorella thermoautotrophica, Moorella sp. 215559 / E30-SF1&2, Moorella sp. 60_41, Moorella sp. AIP 246.00, Moorella sp. AIP 247.00, Moorella sp. AIP 248.00, Moorella sp. AIP 383.98, Moorella sp. AIP 384.98, Moorella sp. AIP 515.00, Moorella sp. auto11, Moorella sp. auto39, Moorella sp. auto54, Moorella sp. auto59, Moorella sp. CF4, Moorella sp. CF5, Moorella sp. E306M, Moorella sp. E308F, Moorella sp. F21, Moorella sp. Hama-1, Moorella sp. HUC22-1, Moorella sp. UBA4076, Moorella sp. Enrichment Clone R19, Moorella sp. Enrichment Clone R2, Moorella sp. Enrichment Clone R65, Moorella sp. Enrichment Culture Clone B1-B-65, Moorella sp. Enrichment Culture Clone B11-B-11, Moorella sp. Enrichment Culture Clone B13-B-103 ... The enrichment clone may be selected from, but is not limited to, any one of cultured Moorella sp. clone B13-B-72, Moorella sp. enrichment clone DGGE-band1, Moorella sp. enrichment clone TERIBC1, Moorella sp. enrichment clone TERIBC2, Moorella sp. enrichment clone TERIBC3, Moorella sp. enrichment clone TERIBC4, Moorella sp. enrichment clone TERIBC5, and uncultured Moorella sp. [see, for example, the National Center for Biotechnology Information (World Wide Web (www) address ncbi.nlm.nih.gov / Taxonomy / Browser / wwwtax.cgi?id=44260; accessed July 1, 2021].

[0084] In other embodiments, the genetically modified bacterium can be any bacterium classified as belonging to the species Moorella thermoacetica and / or Moorella thermoautotrophica. The strain of M. thermoacetica can be selected from, but is not limited to, M. thermoacetica ATCC 39073 and M. thermoacetica Y72 and strains derived therefrom, such as, for example, M. thermoacetica strain 39073-HH. The classification of M. thermoacetica and / or M. thermoautotrophica can be based on resources such as the NCBI Taxonomy Browser (see references above) and / or it can be based on genetic analysis.

[0085] Methods for assessing whether two bacterial strains belong to the same or different species are known in the art, and include average nucleotide identity (ANI) analysis. A particular type of ANI analysis is ANI analysis based on MUMmer alignment (ANIm). Briefly, the genome of target strain is aligned with the genome of reference strain, and matched regions are identified. The percentage of nucleotide identity of matched regions is calculated as the average value of all matched regions. If the comparison of two bacterial strains results in an ANIm score of at least 96.5%, they can be classified as belonging to the same species (Richter et al., PNAS; 106:19126-19131 2009, incorporated by reference in its entirety).

[0086] Use of genetically modified bacteria In one aspect, the invention relates to the use of a genetically modified bacterium according to an embodiment of the invention for metabolizing a carbon-containing substrate in the production of a biochemical product of choice.

[0087] In a preferred embodiment, the carbon-containing substrate is CO and / or CO2. Thus, the genetically modified bacteria as described herein can be suitably used in methods for fixing greenhouse gases such as CO2, which can benefit the environment.

[0088] Carbon-containing substrates Moorella sp. bacteria are naturally capable of growing with H2 / CO2 or CO as the sole carbon source, therefore no further genetic modifications are required to use the genetically modified bacteria according to the invention to metabolize CO and CO2.

[0089] Moorella sp. bacteria also grow naturally on other carbon-containing substrates, including xylose, fructose, methanol, glucose, arabinose, mannose, rhamnose, and pyruvate.

[0090] biochemical substances In an embodiment of the invention, the genetically modified bacteria according to the invention are used in the production of biochemicals.

[0091] The biochemical may be selected from, for example, C1-C4 alcohols, C1-C4 ketones, C1-C4 aldehydes, C1-C4 carboxylic acids, and any mixtures thereof. In some embodiments, the biochemical is selected from acetate, acetone, butanone, and ethanol.

[0092] For the production of a selected biochemical by the genetically modified bacteria according to the present invention, the bacteria may be further genetically modified by introducing into them one or more enzymes useful for the production of the selected biochemical. Usually, the production of a biochemical requires the action of more than one enzyme, and the production of a biochemical often requires the sequential action of multiple enzymes that constitute a specific biosynthetic pathway. The enzyme can be any characterized and sequenced enzyme from any species reported in the literature, so long as it provides the desired activity. In some embodiments, the enzyme is an overexpressed gene that is native to the bacteria. In some embodiments, the enzyme is a functionally active fragment or variant of an enzyme that is heterologous or native to the bacteria. Also, in some embodiments, the recombinant biosynthetic pathway includes knockdown or knockout of one or more genes to avoid competing reactions that would normally reduce the yield of the desired biochemical. To be functional in a thermophilic host cell, the enzyme should be highly thermostable. However, the enzyme does not necessarily have to be derived from a thermophilic organism.

[0093] The introduction of enzymes into bacteria may be performed by transforming the bacteria with one or more vectors, each encoding one or more enzymes under the control of a promoter, ensuring expression of the genes at an appropriate level so that the introduction of the genes does not extract too much substrate or energy in the host cell, as described for the expression of the SinR mutant above. The transformation may be performed as described elsewhere herein. The transformation event introducing the enzymes for the production of the selected biochemical into the cell may be combined, if applicable, with the introduction of any other vectors relevant to the invention, such as a knockout vector for Spo0A and / or a vector encoding a SinR mutant. Some of the genes may be combined on the same vector.

[0094] Four (preferred) examples of biochemicals that can be produced according to the present invention, as well as enzymes suitable for their production, are given below. The biochemicals or biosynthetic pathways should not be considered limiting, but merely exemplary.

[0095] Acetate: Moorella species bacteria, including the acetogenic M. thermoacetica, naturally produce acetate.

[0096] acetone: Production of acetone in Moorella species bacteria, more specifically in M. thermoacetica, can be enabled by introduction of the following enzymes into the bacteria: thiolase (Thl), acetate acetoacetyl-CoA transferase (CtfAB), and acetoacetate decarboxylase (Adc). For examples of synthetic operons useful for acetone production in M. thermoacetica, see Genbank acc number MW436696 (Zeldes et al., Biotechnol. Bioeng.; 115:2951-2961 2018; Kato et al., AMB Expr.; 11:59 2021). The specific operon contains genes encoding Thl from Caldanaerobacter subterraneus, CtfAB from Thermosipho melanesiensis, and Adc from Clostridium acetobutylicum.

[0097] Butanone: The production of butanone in Moorella species bacteria, more specifically in M. thermoacetica, can be made possible by introducing into the bacteria enzymes that catalyze the production of 2,3-butanediol and that convert the resulting 2,3-butanediol to butanone. 2,3-butanediol is produced by converting pyruvate to acetolactate, which is converted to 2,3-butanediol via acetoin, a reaction catalyzed by the enzymes acetolactate synthase (Als), acetolactate decarboxylase (Aldc), and 2,3-butanediol dehydrogenase (Bdh). Subsequent conversion of 2,3-butanediol to butanone can occur by the action of diol hydratases (pduC, pduD, and pduE) found naturally in strains such as Lactobacillus reuteri (Ghiaci et al., Plos One; 9(7):e102774 2014). The second method to produce butanone is to fuse propionyl-CoA with acetyl-CoA to form 3-ketovaleryl-CoA by a promiscuous β-ketothiolase, and then convert 3-ketovaleryl-CoA to butanone by the action of acetoacetyl-CoA:acetate / butyrate:CoA transferase (CftAB) and acetoacetate decarboxylase (Adc), which are commonly expressed in ABE-producing Clostridia (Srirangan et al., Biotechnology; 82:2574-2584 2016).

[0098] ethanol: Ethanol production in Moorella species bacteria, and more specifically in M. thermoacetica, can be possible by using the bifunctional aldehyde / alcohol dehydrogenase (AdhE) enzyme, which converts acetyl-CoA to ethanol, or by acetate reduction to acetaldehyde and further to ethanol via the aldehyde:ferredoxin oxidoreductase (AOR) enzyme and alcohol dehydrogenase (Liew et al., Metab. Eng.; 40:104-114 2017).

[0099] This invention is illustrated by the following examples which should not be construed as limiting. EXAMPLES

[0100] [Example 1]

[0101] Deletion of Spo0A increases the growth rate of M. thermoacetica A circular knockout plasmid was constructed to delete the gene spo0A in M. thermoacetica by homologous recombination.

[0102] The plasmid backbone was pK18, containing the E. coli pMB1 replicon, which is not functional in M. thermoacetica, and a mesophilic kanamycin resistance marker. Two homologous regions, 1 kb each upstream and downstream of M. thermoacetica spo0A, were flanked by a thermophilic kanR resistance marker under the control of the naturally constitutive M. thermoacetica PG3PD promoter (plasmid map shown in Figure 2). The plasmid was constructed by amplifying the fragment using PCR (with high fidelity polymerase) with the primers listed in Table 2. The fragment was assembled using the Gibson method (New England Biolabs). Once the plasmid was constructed and verified by sequencing, the plasmid was transferred into the breeding strain, which also ensured proper DNA methylation.

[0103] [Table 2]

[0104] M. thermoacetica ATCC 39073 was cultivated in 100 ml serum bottles (50% filled) closed with butyl rubber stoppers (bottles and stoppers: Ochs, Germany) according to previously published methods (Daniel et al., J. Bacteriol.; 172:4464-4471 1990; Redl et al., Front. Microbiol.; 10

[3070] 2020). However, the medium was modified by replacing the buffer system with 2-(N-morpholino)ethanesulfonic acid (MES) and utilizing fructose as a carbon source (final concentration 60 mM). The medium had the following composition (in g / l): KH2PO4 (0.5); NH4Cl (0.4); NaCl (0.4); MES (20); yeast extract (0.5); 1% trace element solution was added to the medium. A trace element solution was prepared with 2 g / l nitrilotriacetic acid, the pH was adjusted to 6.0 with KOH, and the following compounds were added (in mg / l): MnSO4·H2O (1000); Fe(SO4)2(NH4)2·6H2O (800); CoCl2·6H2O (200); ZnSO4·7H2O (200); CuCl2·2H2O (20); NiCl2·6H2O (20); Na2MoO4·2H2O (20); Na2SeO4 (20); Na2WO4 (20). The pH of the culture medium was adjusted to 6.5, flushed with N2:CO2 (80:20), and autoclaved at 140 °C for 40 min. The following stock solutions were added after autoclaving: CaCl2 (50 mg / l final), MgCl2 (330 mg / l final), vitamin solution (1%), cysteine-HCl (1 mM final). The vitamin solution contained (in mg / l): biotin (2); folic acid (2); pyridoxine-HCl (10); thiamine-HCl (5); riboflavin (5); nicotinic acid (5); calcium D-(+)-pantothenate (5); vitamin B12 (0.5); p-aminobenzoic acid (5); thioctic acid (5). The medium was pre-warmed before inoculation. The strains were cultivated at 60°C and agitated. The solid medium contained 1% Gelzan™, CaCl2 (100 mg / l), MgCl2 (660 mg / l) and the medium was sterilized at 120°C for 20 min.

[0105] Prior to electroporation, cells were grown to exponential phase, harvested by centrifugation, and washed twice with buffer (5 mM NaH2PO4 / 270 mM sucrose). Approximately 1 μg of plasmid DNA was transformed into cells by electroporation. Electroporation conditions were 1.5 kV, 500Ω by using a Bio-Rad Gene Pulser™ and a cuvette with a 0.2 cm gap (product of Bio-Rad Laboratories, Inc.). For more details, see Kita et al. (J. Biosci. Bioeng.; 115:347-352 2013). Recoveries from electroporation were performed in medium as described above, but with increased concentrations of yeast extract (10 g / L). Recoveries were performed overnight, after which 100 μl of culture (at various dilutions) was plated on solid medium with 400 μg / ml kanamycin. Incubation was performed anaerobically at 60 °C for 4–7 days until colonies appeared on the plates. Colonies were examined for integration by PCR using four primer sets (spo0A_up_ext_250bp-spo0A_dn_ext_250bp, spo0A_up_ext_250bp-Kan_Seq re, Kan_Seq fo-spo0A_dn_ext_250bp, and Kan_Seq re-Spo0A_UP_fo (ext-ext, ext-int, int-ext, and int-int, respectively)). Positive colonies were cultured in liquid medium with 100 μg / ml kanamycin.

[0106] To further verify the transformation, gDNA was extracted from the culture and the whole genome was sequenced, thus confirming that the spo0A gene had been replaced by the kanR cassette.

[0107] Cultures of the WT and Δspo0A strains were grown in media as previously described. After entering stationary growth phase, samples were taken and visually inspected under a microscope (Leica DM5000). Both cultures were evidently remarkably sporulating. This was further confirmed by malachite green spore staining. 0.5% (wt / vol) malachite green in aqueous solution was added to the microscope slides on which the bacterial cells were fixed. The slides were placed over boiling water, and the malachite green was pressed into the spores. After cooling (to room temperature), the excess stain was washed off with water. The stained spores were identified under a microscope (Leica DM5000). Clearly green stained spores were observed in both cultures.

[0108] To further explore the effect of the deletion, both strains were cultivated (in triplicate) and the optical density of the cultures at 600 nm was monitored online. The growth curves are shown in Figure 3. Surprisingly, the phenotype of M. thermoacetica Δspo0A is characterized by a significantly higher growth rate (shorter doubling time), as is evident in the figure and in the growth rates presented in Table 3.

[0109] [Table 3]

[0110] Assessment of significance by t-test (with a confidence interval of 0.05) showed that Δspo0A grew significantly faster than the wild type. [Example 2]

[0111] Changes in the amino acid sequence of SinR from M. thermoacetica To develop a strain less prone to sporulation, an evolution study was set up with M. thermoacetica 39073-HH. Cultures were grown in medium (same as described in Example 1) with 2.5 g / l yeast extract and incubated at 60° C. To apply selection pressure, once the cultures reached stationary phase (usually after 4 days), they were re-inoculated into fresh medium using a 2% inoculum. This approach was continued until the cultures had evolved for approximately 2500 generations (14 transfers).

[0112] Characterization of the cultures grown in the medium and under the conditions used during evolution was performed by microscopy, malachite green staining of the spores (see description in Example 1), and biomass production (by optical density measurements). The evolved cultures did not have disrupted sporulation and biomass production was similar to the non-evolved strain. By storing the cultures in the incubator for extended periods and re-culturing the strains, it was surprisingly observed that they were able to become metabolically active immediately after being quiescent for more than 25 days, in contrast to the wild type, which usually has a significant lag phase after 1-3 days of being quiescent.

[0113] To assess genetic changes that occurred during evolution, cultures were plated on solid medium at various dilutions (to allow growth of single colonies) and incubated anaerobically at 60°C for 7 days. Six single colonies were picked and cultured in liquid medium. After 2 days of incubation, cells were spun down and genomic DNA was extracted from each culture using the Wizard® Genomic DNA Purification Kit (Promega, Madison, WI, USA), and the extracted DNA was dissolved in 10 mM Tris-Cl, pH 8.5. DNA quantification was performed using the Qubit dsDNA HS Assay Kit on a Qubit 2.0 fluorometer (Thermo Fisher Scientific, Waltham, MA, USA). The DNA was used to generate an Illumina shotgun sequencing library. Sequencing was performed (600 cycles) using the MiSeq system with the MiSeq Reagent Kit v3, as recommended by the manufacturer (Illumina, San Diego, CA, USA), resulting in 2 × 300 bp paired-end reads. Dominant mutations were identified by aligning to the reference genome sequence. The only mutation associated with the cell condition was the V198F mutation in the gene encoding SinR.

[0114] The evolved strains had non-collapsed sporulation, whereas the wild type (carrying SinR_198V) was most likely to produce spores and had a cell morphology that was more circular rather than the characteristic rod shape. The evolved strains with 198F had a more characteristic rod-shaped morphology and tended to aggregate. When used as inoculum into fresh medium, cultures carrying SinR_198F had a significantly shorter lag phase.

[0115] Analysis of the protein structure of M. thermoacetica SinR indicates that M. thermoacetica SinR resembles Bacillus SinR, but the two proteins are not identical. Sequence alignment of the third HTH domain from SinR in M. thermoacetica and SinR from B. subtilis uses two different alignment algorithms. Without being limited by theory, this suggests that V198 in M. thermoacetica may be equivalent to either T60 or L61 in B. subtilis. SinR in B. subtilis has an unambiguous crystal structure that has allowed further analysis of changes in binding to other proteins or oligomerization. Examination of the structure of the SinR-SinI complex from B. subtilis, both SinR oligomerization and SinI binding [SinI binding mimics the oligomerization interaction (Bai et al., Genes Dev.; 7:139-148 1993, Lewis et al., J. Mol. Biol.; 283:907-912 1998)] shows that T60 and L61 reside in an interphase between the HTH and oligomerization domains (Fig. 4). The side chain of L61 faces the inside of the helix-turn-helix motif, and mutation of this to Phe(F) results in a steric clash and possibly protein destabilization (Fig. 4C). The side chain of T60 faces the oligomerization domain and makes two hydrogen bonds with E14 from SinI (Fig. 4D, left). Mutation of T60 to F eliminated the hydrogen-bonding ability, most likely resulting in a steric clash between SinR and SinI, reducing affinity ( Fig. 4D , middle and left).

[0116] Structural analysis found that L61 faces the protein core of SinR, and therefore mutations at L61 are expected to destabilize SinR. T60 faces the intermediate phase of SinI interaction, and therefore mutations at this residue are expected to affect the affinity of SinR-SinI interaction. To confirm these hypotheses and identify other mutations predicted to have similar effects on either SinR protein stability and / or SinI interaction affinity, two different bioinformatics tools were applied: (i) the PremPS server (Chen et al., PLOS Comp. Biol.; 16:e1008543 2020) was used to calculate the predicted effects on SinR protein stability, and (ii) the mCSM-PPI2 server (Rodrigues et al., Nucleic Acids Res.; 47:W338-W344 2019) was used to calculate the predicted effects on SinI interaction affinity. In both cases, the effects of all possible mutations at both T60 and L61 were predicted.

[0117] Bioinformatics predictions for mutations at L61 (Table 4) suggest that mutations at this position have a large effect on protein stability, whereas the effect on SinI interaction affinity is less pronounced. This is consistent with structural analysis showing that L61 faces the protein core and does not form part of the SinI interaction site. Based on these observations, the major contributor to any phenotypic effects observed upon mutation of L61 is expected to be protein stability. Analysis of individual mutations at L61 shows that all mutations are predicted to be destabilizing, with L61F being the least destabilizing (predicted ΔΔG 安定性 (kcal / mol)=0.15), L61S is the most destabilized (predicted ΔΔG 安定性If SinR V198 in M. thermoacetica is homologous to L61 in Bacillus subtilis, as suggested by previous sequence alignments, mutation of V198 to any amino acid would be expected to destabilise M. thermoacetica SinR and therefore have phenotypic effects similar to those observed for V198F.

[0118] Contrary to what was predicted for L61, mutations at T60 were predicted to have a large effect on the interaction affinity between SinR and SinI, whereas the effect on protein stability was predicted to be less pronounced (Table 5). This is expected from the structural analysis since T60 resides in the interphase of the SinR-SinI interaction and faces the SinR surface. Given these results, the main phenotypic effect of mutations at T60 is expected to result from changes in affinity for SinI. Evaluation of the individual mutations shows that two mutations, T60D and T60E, are predicted to increase affinity for SinI. This is easily explained upon inspection of the modeled mutant structures where both aspartate and glutamate make several new polar and hydrogen bonding contacts to SinI. The remainder of the mutations (all amino acids other than aspartate and glutamate) are predicted to decrease affinity for SinI. This is in good agreement with the structural analysis, where the side chain of T60 was found to make two hydrogen bonds with E14 from SinI. Mutation of T60 removes the hydrogen-bonding ability and reduces the affinity between SinR and SinI. If SinR V198 in M. thermoacetica is homologous to T60 in Bacillus, as suggested by the previous sequence alignment, mutation of V198 to any amino acid except aspartate and glutamate is expected to reduce the SinR-SinI interaction affinity and thus have a phenotypic effect similar to that observed for V198F.

[0119] [Table 4]

[0120] [Table 5]

[0121] List of References Each of the references listed below or described elsewhere in this specification is incorporated herein by reference in its entirety.

Claims

1. A method for increasing the growth rate of a bacterium belonging to the Moorella species, comprising introducing one or more genetic modifications into the bacterium to reduce or eliminate the expression and / or activity of stage 0 sporulation protein A homologue (Spo0A) in the bacterium.

2. 2. The method of claim 1, wherein the one or more genetic modifications include a genetic modification that reduces or eliminates expression of SpoOA protein in the bacterium.

3. The method described in claim 1, wherein the reduction in expression and / or activity of Spo0A in the bacterium is at least 25%, such as at least 50%, such as at least 75%, such as at least 90%, and such as at least 95%, compared to the bacterium before introduction of the one or more genetic modifications.

4. The method of claim 1 , wherein the spoOA gene is deleted.

5. The method of claim 1, further comprising introducing one or more genetic modifications into the bacterium to express a mutant SinR in the bacterium, wherein the SinR mutant has at least 90% sequence identity with SEQ ID NO: 2 and comprises an amino acid other than V at a position corresponding to position 198 in SEQ ID NO: 2, preferably the amino acid is F, I, Y, or W, more preferably the amino acid is F, and the SinR mutant provides a reduced duration of the lag phase and / or an increased growth rate of the bacterium when compared to SEQ ID NO:

2.

6. 6. The method of claim 5, wherein the amino acid at the position corresponding to position 198 in SEQ ID NO: 2 is phenylalanine (F), isoleucine (I), tyrosine (Y), or tryptophan (W).

7. 7. The method of claim 6, wherein the amino acid at the position corresponding to position 198 in SEQ ID NO: 2 is F.

8. The Moorella species (a) Moorella thermoacetica; (b) Moorella thermoautotrophica; (c) M. thermoacetica strain DSM 512 Ｔ a bacterial strain having an average nucleotide identity based on a MUMmer alignment (ANIm) score of at least about 96.5% compared to (d) M. thermoacetica strain DSM 2955 Ｔ a bacterial strain having an average nucleotide identity based on a MUMmer alignment (ANIm) score of at least about 96.5% compared to (e) (a) and (b); (a) and (c); (a) and (d); (a), (b) and (c), or all combinations of (a) through (d). The method of claim 1 , wherein the compound is selected from the group consisting of:

9. 1. A bacterium belonging to the species M. thermoacetica and / or M. thermoautotrophica, wherein the bacterium has been genetically modified to reduce or eliminate expression and / or activity of SpoOA in the bacterium, wherein the reduced expression and / or activity is relative to its expression and / or activity in wild-type M. thermoacetica and / or M. thermoautotrophica.

10. A bacterium belonging to the species M. thermoacetica and / or M. thermoautotrophica, wherein the bacterium is: (a) a variant of SinR having at least 90% sequence identity to SEQ ID NO:2 and comprising an amino acid other than V at a position corresponding to position 198 in SEQ ID NO:2, wherein the SinR variant provides a decreased duration of lag phase and / or an increased growth rate of the bacterium when compared to SEQ ID NO:2; (b) a bacterium having reduced or eliminated expression and / or activity of SpoOA, wherein said reduced expression and / or activity is relative to its expression and / or activity in wild-type M. thermoacetica and / or M. thermoautotrophica.

11. The bacterium according to claim 9 , wherein the spoOA gene is deleted.

12. The bacterium according to claim 10, wherein the amino acid at the position corresponding to position 198 in SEQ ID NO: 2 is F.

13. 13. Use of a bacterium according to any one of claims 9 to 12 for metabolising a carbon-containing substrate, optionally in the production of a biochemical.

14. i) the carbon-containing substrate is CO and / or CO ２ Or ii) the biochemical is selected from C1-C4 alcohols, C1-C4 ketones, C1-C4 aldehydes, C1-C4 carboxylic acids, and any mixture thereof; or iii) The use according to claim 13, wherein both i) and ii) are true.

15. The method of any one of claims 1 to 8, or the bacterium of any one of claims 9 to 12, wherein the bacterium is M. thermoacetica ATCC 39073 strain or a strain derived therefrom, such as M. thermoacetica ATCC 39073-HH strain.

16. The Moorella species (a) Moorella thermoacetica; (b) Moorella thermoautotrophica; (c) a bacterial strain having an average nucleotide identity based on a MUMmer alignment (ANIm) score of at least about 96.5% compared to M. thermoacetica strain DSM 512 T ; (d) a bacterial strain having an average nucleotide identity based on a MUMmer alignment (ANIm) score of at least about 96.5% compared to M. thermoacetica strain DSM 2955 T ; and (e) (a) and (b); (a) and (c); (a) and (d); (a), (b) and (c), or all combinations of (a) through (d). The method according to any one of claims 2 to 7, wherein the compound is selected from the group consisting of:

17. The use according to claim 13, wherein the bacterium is M. thermoacetica ATCC 39073 strain or a strain derived therefrom, such as M. thermoacetica ATCC 39073-HH strain.

18. The use according to claim 14, wherein the bacterium is M. thermoacetica ATCC 39073 strain or a strain derived therefrom, such as M. thermoacetica ATCC 39073-HH strain.

19. The method described in claim 2, wherein the reduction in expression and / or activity of Spo0A in the bacterium is at least 25%, such as at least 50%, such as at least 75%, such as at least 90%, and such as at least 95%, compared to the bacterium before introduction of the one or more genetic modifications.

20. A method according to any one of claims 2 to 4, further comprising introducing one or more genetic modifications into the bacterium to express a mutant SinR in the bacterium, wherein the SinR mutant has at least 90% sequence identity with SEQ ID NO: 2 and comprises an amino acid other than V at a position corresponding to position 198 in SEQ ID NO: 2, preferably wherein the amino acid is F, I, Y, or W, more preferably wherein the amino acid is F, and wherein the SinR mutant provides a reduced duration of the lag phase and / or an increased growth rate of the bacterium when compared to SEQ ID NO:

2.

21. The method described in claim 20, wherein the amino acid at the position corresponding to position 198 in SEQ ID NO: 2 is phenylalanine (F), isoleucine (I), tyrosine (Y), or tryptophan (W).

22. The method described in claim 21, wherein the amino acid at the position corresponding to position 198 in sequence number 2 is F.

23. A bacterium described in claim 10, in which the spo0A gene is deleted.

Images